Gene-editing experts scrutinise Huidagene trial decisions following patient death
Specialists in gene editing have questioned the study design and technical choices made by Huidagene Therapeutics in a Duchenne muscular dystrophy trial in which a patient died.
Experts in gene editing and clinical trial design are examining the decisions made by the Chinese biotechnology company Huidagene Therapeutics following the death of a patient enrolled in its Duchenne muscular dystrophy (DMD) programme. Stat News reported on 19 August 2026 that specialists are questioning technical modifications Huidagene implemented in a treatment strategy that has largely been discontinued by United States-based companies, citing safety and efficacy concerns.
The scrutiny centres on the specific genome-editing approach employed and on how trial disclosures were made after the adverse event. Experts quoted by Stat News raised concerns about whether the modifications Huidagene introduced adequately addressed the known risks associated with the underlying strategy, and about the transparency of reporting.
The case follows a broader pattern of international concern about clinical trial governance in novel genome-editing studies. Genetic Current covered related developments — including an earlier death in a Chinese gene-editing trial — in its 6 August 2026 cluster on gene-editing trial safety and research ethics.
This story is relevant to researchers working in genome editing, genetic counsellors and clinicians who advise families affected by DMD, and to those with an interest in research ethics and regulatory oversight of early-phase gene therapy studies. The underlying DMD biology involves loss-of-function variants in the dystrophin gene (*DMD*) on the X chromosome.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
A company in China called Huidagene was testing a new gene-editing treatment for Duchenne muscular dystrophy, a serious genetic muscle condition caused by faults in a gene called DMD. A patient in the trial died, and experts in gene editing are now looking closely at the decisions the company made when designing and running the trial. They are asking whether the particular approach used was safe and whether the company was open enough about what happened. Gene-editing treatments use molecular tools to try to correct or work around faults in DNA inside cells. Because these technologies are new and still being studied, trials are closely watched for safety. Researchers, medical regulators, and ethics experts say transparency after adverse events in trials is important for the whole field. This story does not relate to any currently available treatment. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-08-19STAT+: In wake of boy's death, gene editing experts dissect Huidagene's decisions
-
Stat News · 2026-08-19STAT+: Experts scrutinize Huidagene's disclosures after patient death